{"id":68904,"date":"2026-04-09T17:28:12","date_gmt":"2026-04-09T11:58:12","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=68904"},"modified":"2026-04-09T17:28:14","modified_gmt":"2026-04-09T11:58:14","slug":"lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/","title":{"rendered":"Lupin Share Price Target 2026: Analyst Forecast, Bull &amp; Bear Case"},"content":{"rendered":"<p>Lupin (NSE: LUPIN) is trading at Rs 1,880 as of April 2026, against a 52-week high of undefined and a 52-week low of undefined. The analyst consensus 12-month Lupin share price target stands at Rs 2,200-2,500 \u2014 implying meaningful upside from current levels. This article covers the current share price, key catalysts, risks, technical support levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term share price targets.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Current_Price_Overview\" title=\"Current Price Overview\">Current Price Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#About_Lupin\" title=\"About Lupin\">About Lupin<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Key_Catalysts_Driving_Lupin_Share_Price\" title=\"Key Catalysts Driving Lupin Share Price\">Key Catalysts Driving Lupin Share Price<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#1_US_Specialty_%E2%80%94_Spiriva_Respimat_Generic\" title=\"1. US Specialty \u2014 Spiriva Respimat Generic\">1. US Specialty \u2014 Spiriva Respimat Generic<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#2_Lupins_generic_Spiriva_Respimat_tiotropium_has_first-to-file_exclusivity_in_the_US_for_a_product_with_Rs_1500-2000_crore_quarterly_peak_revenue_potential_Launch_timing_depends_on_patent_litigation_outcome_%E2%80%94_a_positive_ruling_would_be_a_major_positive_catalyst\" title=\"2. Lupin&#8217;s generic Spiriva Respimat (tiotropium) has first-to-file exclusivity in the US for a product with Rs 1,500-2,000 crore quarterly peak revenue potential. Launch timing depends on patent litigation outcome \u2014 a positive ruling would be a major positive catalyst.\">2. Lupin&#8217;s generic Spiriva Respimat (tiotropium) has first-to-file exclusivity in the US for a product with Rs 1,500-2,000 crore quarterly peak revenue potential. Launch timing depends on patent litigation outcome \u2014 a positive ruling would be a major positive catalyst.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#3_Biosimilar_Pegfilgrastim_%E2%80%94_Nyvepria\" title=\"3. Biosimilar Pegfilgrastim \u2014 Nyvepria\">3. Biosimilar Pegfilgrastim \u2014 Nyvepria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#4_Lupins_Nyvepria_pegfilgrastim_biosimilar_is_gaining_market_share_in_the_US_%E2%80%94_the_global_G-CSF_market_is_approximately_25_billion_Each_percentage_point_of_market_share_represents_approximately_Rs_200-250_crore_revenue\" title=\"4. Lupin&#8217;s Nyvepria (pegfilgrastim biosimilar) is gaining market share in the US \u2014 the global G-CSF market is approximately $2.5 billion. Each percentage point of market share represents approximately Rs 200-250 crore revenue.\">4. Lupin&#8217;s Nyvepria (pegfilgrastim biosimilar) is gaining market share in the US \u2014 the global G-CSF market is approximately $2.5 billion. Each percentage point of market share represents approximately Rs 200-250 crore revenue.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#5_India_Branded_Business_Recovery\" title=\"5. India Branded Business Recovery\">5. India Branded Business Recovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#6_Lupins_India_branded_formulations_%E2%80%94_Ondero_Linagliptin_Gluconorm_Metformin_Rosuvast_%E2%80%94_are_growing_at_10-12_as_the_branded_generic_market_recovers_post-COVID_disruption\" title=\"6. Lupin&#8217;s India branded formulations \u2014 Ondero (Linagliptin), Gluconorm (Metformin), Rosuvast \u2014 are growing at 10-12% as the branded generic market recovers post-COVID disruption.\">6. Lupin&#8217;s India branded formulations \u2014 Ondero (Linagliptin), Gluconorm (Metformin), Rosuvast \u2014 are growing at 10-12% as the branded generic market recovers post-COVID disruption.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#7_Japan_Generic_Market_%E2%80%94_Lupins_Global_Differentiation\" title=\"7. Japan Generic Market \u2014 Lupin&#8217;s Global Differentiation\">7. Japan Generic Market \u2014 Lupin&#8217;s Global Differentiation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#8_Lupin_has_a_meaningful_Japan_generics_business_Rs_800-1000_crore_revenue_%E2%80%94_rare_among_Indian_pharma_Japans_generic_market_is_growing_at_5-7_as_the_government_promotes_generic_substitution\" title=\"8. Lupin has a meaningful Japan generics business (Rs 800-1,000 crore revenue) \u2014 rare among Indian pharma. Japan&#8217;s generic market is growing at 5-7% as the government promotes generic substitution.\">8. Lupin has a meaningful Japan generics business (Rs 800-1,000 crore revenue) \u2014 rare among Indian pharma. Japan&#8217;s generic market is growing at 5-7% as the government promotes generic substitution.<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Key_Risks_to_Lupin_Share_Price\" title=\"Key Risks to Lupin Share Price\">Key Risks to Lupin Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Technical_Analysis_and_Support_Levels\" title=\"Technical Analysis and Support Levels\">Technical Analysis and Support Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Latest_Quarterly_Financial_Performance\" title=\"Latest Quarterly Financial Performance\">Latest Quarterly Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Institutional_Positioning_%E2%80%94_FII_DII_Promoter\" title=\"Institutional Positioning \u2014 FII, DII, Promoter\">Institutional Positioning \u2014 FII, DII, Promoter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Lupin_Share_Price_Target_2026\" title=\"Lupin Share Price Target 2026\">Lupin Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Short-Term_Target_3%E2%80%936_Months\" title=\"Short-Term Target (3\u20136 Months)\">Short-Term Target (3\u20136 Months)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#12-Month_Analyst_Target\" title=\"12-Month Analyst Target\">12-Month Analyst Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Long-Term_Target_2027%E2%80%932028\" title=\"Long-Term Target (2027\u20132028)\">Long-Term Target (2027\u20132028)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#FAQs\" title=\"FAQs\">FAQs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-target-2026-analyst-forecast-bull-amp-bear-case\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Price_Overview\"><\/span><strong>Current Price Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Value<\/strong><\/td><\/tr><tr><td>Current Market Price (CMP)<\/td><td>Rs 1,880<\/td><\/tr><tr><td>52-Week High<\/td><td>undefined<\/td><\/tr><tr><td>52-Week Low<\/td><td>undefined<\/td><\/tr><tr><td>Market Cap<\/td><td>Rs 85,600 Cr<\/td><\/tr><tr><td>P\/E Ratio<\/td><td>26x<\/td><\/tr><tr><td>12M Analyst Target<\/td><td>Rs 2,200-2,500<\/td><\/tr><tr><td>Bull Case<\/td><td>Rs 2,800<\/td><\/tr><tr><td>Bear Case<\/td><td>Rs 1,400<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Lupin\"><\/span><strong>About Lupin<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Click Here \u2013 Get Free Investment Predictions<\/a><\/p><p>Lupin (NSE: LUPIN) is a leading listed company in the Pharma sector with a market capitalisation of Rs 85,600 Cr. The company operates across its core business segments and is well-positioned for the Indian economic growth cycle.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Catalysts_Driving_Lupin_Share_Price\"><\/span><strong>Key Catalysts Driving Lupin Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_US_Specialty_%E2%80%94_Spiriva_Respimat_Generic\"><\/span><strong>1. US Specialty \u2014 Spiriva Respimat Generic<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Lupins_generic_Spiriva_Respimat_tiotropium_has_first-to-file_exclusivity_in_the_US_for_a_product_with_Rs_1500-2000_crore_quarterly_peak_revenue_potential_Launch_timing_depends_on_patent_litigation_outcome_%E2%80%94_a_positive_ruling_would_be_a_major_positive_catalyst\"><\/span><strong>2. Lupin&#8217;s generic Spiriva Respimat (tiotropium) has first-to-file exclusivity in the US for a product with Rs 1,500-2,000 crore quarterly peak revenue potential. Launch timing depends on patent litigation outcome \u2014 a positive ruling would be a major positive catalyst.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Biosimilar_Pegfilgrastim_%E2%80%94_Nyvepria\"><\/span><strong>3. Biosimilar Pegfilgrastim \u2014 Nyvepria<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Lupins_Nyvepria_pegfilgrastim_biosimilar_is_gaining_market_share_in_the_US_%E2%80%94_the_global_G-CSF_market_is_approximately_25_billion_Each_percentage_point_of_market_share_represents_approximately_Rs_200-250_crore_revenue\"><\/span><strong>4. Lupin&#8217;s Nyvepria (pegfilgrastim biosimilar) is gaining market share in the US \u2014 the global G-CSF market is approximately $2.5 billion. Each percentage point of market share represents approximately Rs 200-250 crore revenue.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_India_Branded_Business_Recovery\"><\/span><strong>5. India Branded Business Recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"6_Lupins_India_branded_formulations_%E2%80%94_Ondero_Linagliptin_Gluconorm_Metformin_Rosuvast_%E2%80%94_are_growing_at_10-12_as_the_branded_generic_market_recovers_post-COVID_disruption\"><\/span><strong>6. Lupin&#8217;s India branded formulations \u2014 Ondero (Linagliptin), Gluconorm (Metformin), Rosuvast \u2014 are growing at 10-12% as the branded generic market recovers post-COVID disruption.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"7_Japan_Generic_Market_%E2%80%94_Lupins_Global_Differentiation\"><\/span><strong>7. Japan Generic Market \u2014 Lupin&#8217;s Global Differentiation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"8_Lupin_has_a_meaningful_Japan_generics_business_Rs_800-1000_crore_revenue_%E2%80%94_rare_among_Indian_pharma_Japans_generic_market_is_growing_at_5-7_as_the_government_promotes_generic_substitution\"><\/span><strong>8. Lupin has a meaningful Japan generics business (Rs 800-1,000 crore revenue) \u2014 rare among Indian pharma. Japan&#8217;s generic market is growing at 5-7% as the government promotes generic substitution.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Risks_to_Lupin_Share_Price\"><\/span><strong>Key Risks to Lupin Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><strong>Spiriva litigation adverse outcome delaying US launch:&nbsp;<\/strong><\/p><p><strong>Pegfilgrastim biosimilar pricing pressure from Amgen Neulasta:&nbsp;<\/strong><\/p><p><strong>India branded margin pressure from channel destocking:&nbsp;<\/strong><\/p><p><strong>FDA inspection risk:&nbsp;<\/strong><\/p><p>The 26% US reciprocal tariff on Indian goods \u2014 announced April 2, 2026 \u2014 has created a macro overhang affecting all Indian equities through FII outflows and earnings estimate revisions. Resolution of tariff uncertainty would be a meaningful positive catalyst for re-rating.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Technical_Analysis_and_Support_Levels\"><\/span><strong>Technical Analysis and Support Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Lupin is trading at Rs 1,880 vs. a 52-week range of undefined to undefined. Key technical support is at Rs 1,780-2,000. The 200-day moving average provides medium-term guidance for trend direction.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Lupin&#8217;s live price and get daily research insights.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Latest_Quarterly_Financial_Performance\"><\/span><strong>Latest Quarterly Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Key Metric<\/strong><\/td><td><strong>Latest Quarter<\/strong><\/td><td><strong>Year-Ago Quarter<\/strong><\/td><td><strong>YoY Change<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 5,482 Cr<\/td><td>Rs 4,748 Cr<\/td><td>+15.5%<\/td><\/tr><tr><td>Net Profit<\/td><td>Rs 748 Cr<\/td><td>Rs 564 Cr<\/td><td>+32.6%<\/td><\/tr><tr><td>EBITDA Margin<\/td><td>22.8%<\/td><td>20.4%<\/td><td>+240 bps<\/td><\/tr><tr><td>US Revenue<\/td><td>Rs 2,420 Cr<\/td><td>Rs 2,080 Cr<\/td><td>+16.3%<\/td><\/tr><\/tbody><\/table><\/figure><p>Track Lupin&#8217;s live financials on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Institutional_Positioning_%E2%80%94_FII_DII_Promoter\"><\/span><strong>Institutional Positioning \u2014 FII, DII, Promoter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Promoter holds 46.9%. FII holding is 16.4% and DII holds 14.2%. Institutional holding trends are a critical leading indicator for price direction. Rising FII holding typically precedes price recovery; declining FII signals ongoing caution. Track institutional flow changes on Univest Screener.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Lupin_Share_Price_Target_2026\"><\/span><strong>Lupin Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/user\/log-in\">Subscribe to Univest Pro for Premium Stock Research and F&amp;O Setups<\/a><\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Short-Term_Target_3%E2%80%936_Months\"><\/span><strong>Short-Term Target (3\u20136 Months)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Short-term support and trading range: Rs 1,780-2,000. In the near term, the stock is likely to remain in this band pending clarity on Q4 FY26 results and FY27 guidance. Any macro positive from India-US tariff negotiations would accelerate a move toward the upper end of this range.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"12-Month_Analyst_Target\"><\/span><strong>12-Month Analyst Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 12-month analyst consensus for Lupin is Rs 2,200-2,500. The bear case \u2014 if FY27 guidance disappoints or macro headwinds intensify \u2014 is Rs 1,400. The bull case \u2014 on full earnings delivery and macro recovery \u2014 is Rs 2,800. These are analyst estimates based on publicly available data and may differ materially from actual price performance.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Long-Term_Target_2027%E2%80%932028\"><\/span><strong>Long-Term Target (2027\u20132028)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>For 2027-2028, analysts project Lupin toward the Rs 3,000-3,500 range \u2014 assuming FY27 guidance delivery and normalisation of macro headwinds. Track live targets on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The Lupin share price target for 2026 is Rs 2,200-2,500 based on analyst consensus. The bear case is Rs 1,400 and the bull case is Rs 2,800. At Rs 1,880, Lupin is trading at 26x P\/E with market cap of Rs 85,600 Cr. Whether this is a buy depends on your risk tolerance, investment horizon, and portfolio context. For more share price target analysis, visit&nbsp;<\/p><p><a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a><\/p><p><strong>Disclaimer: <\/strong>This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><strong>Q1. What is Lupin share price target for 2026?<\/strong><\/p><p>The 12-month analyst consensus is Rs 2,200-2,500. Bull case: Rs 2,800. Bear case: Rs 1,400.<\/p><p><strong>Q2. Is Lupin a good buy at Rs 1,880?<\/strong><\/p><p>At 26x P\/E and Rs 1,880, Lupin offers potential recovery to Rs 2,200-2,500 over 12 months. Consult a SEBI-registered financial advisor before investing.<\/p><p><strong>Q3. What are the key risks for Lupin?<\/strong><\/p><p>Key risks include macro headwinds from US tariffs, sector-specific challenges, and any guidance miss in Q4 FY26 results. Monitor institutional holding trends on Univest Screener.<\/p><p><strong>Q4. What is Lupin long-term share price target?<\/strong><\/p><p>Long-term target for FY28 is Rs 3,000-3,500, contingent on sustained earnings delivery and macro recovery.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/coal-india-share-price-target-2026\">Coal India Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/bharti-airtel-share-price-target\">Bharti Airtel Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/state-bank-of-india-share-price-target\">State Bank of India Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/paytm-share-price-target\">Paytm Share Price Target 2026: Analyst Forecasts, Bull &amp; Bear Case<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Lupin (NSE: LUPIN) is trading at Rs 1,880 as of April 2026, against a 52-week high of undefined and a 52-week low of undefined. The analyst consensus 12-month Lupin share price target stands at Rs 2,200-2,500 \u2014 implying meaningful upside from current levels. This article covers the current share price, key catalysts, risks, technical support<\/p>\n","protected":false},"author":27,"featured_media":68908,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3972],"class_list":["post-68904","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-share-price-target"],"metadata":{"_edit_lock":["1775736118:27"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["73"],"rank_math_title":["Lupin Share Price Target 2026: Analyst Forecast, Bull &amp; Bear Case"],"rank_math_description":["Lupin share price target 2026 \u2014 CMP Rs 1,880, consensus Rs 2,200-2,500. US specialty Spiriva, biosimilar Pegfilgrastim, India branded recovery. Bull case Rs 2,800.\n"],"rank_math_focus_keyword":["Lupin Share Price Target"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["68908"],"_edit_last":["27"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7690"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09172331\/Lupin-Share-Price-Target-2.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=68904"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68904\/revisions"}],"predecessor-version":[{"id":68915,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68904\/revisions\/68915"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/68908"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=68904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=68904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=68904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}